Philadelphia Startup Received Funding for Hemorrhage Tech
A new AI tool aimed at predicting postpartum bleeding has secured investment for upcoming clinical trials.
Updated on Sept. 30, 2026 in Pregnancy
Live Poll
Should hospitals prioritize medical technologies designed for existing equipment to lower healthcare costs?
The Philadelphia-based startup Vasowatch has received a $250,000 investment from the University of Pennsylvania StartUP Fund. The company is developing an algorithm designed to predict postpartum hemorrhage risk using existing hospital heart-rate data.
Why it matters
Postpartum hemorrhage is a significant global health challenge that contributes to nearly 43,000 deaths annually. By integrating with existing hospital equipment, this technology aims to improve the early detection of severe blood loss during the recovery period.
Vasowatch has secured $250,000 in capital to support the development of a patented heart-rate analysis system. While the technology has been studied in an observational capacity at Pennsylvania Hospital, its clinical effectiveness is currently being tested in preparation for future trials.
The players
Vasowatch
A Philadelphia-based health technology company developing heart-rate analysis software to detect postpartum hemorrhage.
University of Pennsylvania
An academic institution that established a $10 million StartUP Fund to support emerging health and technology ventures.
SWAN Impact Network
An investment group that provided funding to support the development of the company's hemorrhage prediction technology.
The details
The software functions by continuously analyzing heart-rate data streamed from standard hospital monitoring devices already present in maternal care units. By detecting physiological patterns associated with blood loss, the algorithm generates alerts for clinical staff to facilitate earlier interventions. This design is specifically intended to reduce costs and complexity by avoiding the need for new, specialized bedside hardware.
Timeline
January 2027: Planned start date for the pivotal clinical trial.
Mid-2028: Target date for seeking FDA authorization for the algorithm.
Health Landscape
This development follows a trend of leveraging existing hospital infrastructure to improve maternal outcomes via predictive analytics. It represents a shift toward integrating digital monitoring tools into routine postpartum care to address the ongoing challenge of delayed hemorrhage recognition.
This technology is currently in development and not yet available for patient use in clinical settings. Expectant parents should discuss standard postpartum hemorrhage screening protocols and monitoring practices with their OB-GYN or hospital care team.
The takeaway
Postpartum hemorrhage remains a leading cause of maternal complications, making early identification critical to patient safety. Patients should prioritize understanding their birth facility's monitoring capabilities and current protocols for responding to rapid blood loss.
Further reading
Learn more about maternal monitoring tools in our Pregnancy section.
Source note: This article includes information reported by Technical.
Live Poll
Should hospitals prioritize medical technologies designed for existing equipment to lower healthcare costs?
